Abstract
Purpose. Encapsulation of doxorubicin in niosomes was sought as a route to tumour targeting and improved tumoricidal through the alteration of doxorubicin pharmacokinetics and metabolism.
Methods. Doxorubicin niosomes (10 mg kg−l doxorubicin) prepared from sorbitan monostearate (Span 60), cholesterol and choleth-24 (a 24 oxyethylene cholesteryl ether) in the molar ratio 45:45:10 were administered intravenously to female NMRI mice bearing the MAC 15A subcutaneously implanted tumour. Plasma doxorubicin was fractionated by gel filtration and quantified by HPLC with fluorometric detection as niosome-associated doxorubicin and released doxorubicin. Tumoricidal activity of the formulation was assessed by the intravenous injection of 5 mg kg−1 and 10 mg kg−1 doxorubicin niosomes to male NMRI mice bearing a 6 day old MAC 15A tumour.
Results. At least 90% of the plasma doxorubicin was associated with the niosome fraction 4 h after dosing, and 50% was still associated after 24 h. The clearance of doxorubicin released from the niosomes was about 10 fold greater than the clearance of niosomal doxorubicin (176.5 mL h−l and 16.2 mL h−1, respectively). The area under the plasma level-time curve increased 6 fold when doxorubicin was administered in niosomes, compared to doxorubicin solution (66.0 µg.h mL−l and 10.3 µg.h mL−1, respectively). The area under the tumour level time curve was increased by over 50% by the administration of doxorubicin in niosomes when compared to the drug administered in solution (58.6 µg.h mL−l and 34.3 µg.h mL−1, respectively). There was no statistically significant difference between levels of the drug in the heart when niosomal doxorubicin or doxorubicin solution were administered. Doxorubicin metabolites, namely doxorubicinol and the aglycones doxorubicinone, doxorubicinolone and 7-deoxydoxorubicinone, were found associated with the niosomes in the plasma, possibly due to their adsorption to the vesicle surface once formed outside the niosome. Overall metabolite levels in the liver were increased when doxorubicin niosomes were administered compared to the drug in solution. A 5 mg kg−1 injection of doxorubicin niosomes produced a terminal mean tumour weight that was similar to that obtained from animals administered 10 mg kg−1 doxorubicin solution.
Conclusions. Modest tumour targeting was achieved by the delivery of doxorubicin in sorbitan monostearate niosomes, increasing the tumour to heart AUC0–24 ratio from 0.27 to 0.36 and a doubling of tumoricidal activity. The overall level of doxorubicin metabolites was also increased.
Similar content being viewed by others
REFERENCES
P. Calabaresi and P. Chabner. Antineoplastic agents. In A. Goodman Gilman, T. W. Rall, S. A. Nies, P. Taylor, (eds), Goodman and Gilman's Pharmacological Basis of Therapeutics (8th edition), 1990, Pergamon Press: New York, pp. 1209–1263.
C. Verdun, F. Brasseur, H. Vranckx, P. Couvreur, M. Roland. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother. Pharmacol. 26: 13–18 (1990).
O. Ike, Y. Shimizu, Y. Ikada, S. Wanatabe, T. Natsume, R. Wada, S.-H. Hyon, S. Hitomi. Biodegradation and antitumour effect of adriamycin-containing poly(L-lactic acid) microspheres. Biomaterials, 12: 757–762 (1991).
E. H. Herman, A. Rahman, A. Ferrans, J. A. Vick, and P. S. Schein. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res. 43: 5427–5432 (1983).
A. Gabizon, R. Chisin, S. Anselem, S. Druckman, R. Cohen, D. Goren, I. Fromer, T. Peretz, A. Sulkes, and Y. Barenholz. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer 64: 1125–1132 (1991).
U. R. Hengge, N. H. Brockmeyer, M. Baumann, G. Reiman, and M. Groos. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Lancet 342: 497.
A. Gabizon, A. Dagan, D. Goren, Y. Barenholz, and Z. Fuks. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumour activity in mice. Cancer Res. 42: 4734–4739 (1982).
A. A. Gabizon. Selective tumour localisation and improved therapeutic index of anthracyclines encapsulated in long circulating liposomes. Cancer Res. 52: 891–896 (1992).
J. W. Cowens, P. J. Creaven, W. R. Geco, D. E. Brenner, Y. Tung, M. Ostro, F. Pilkiewicz, R. Ginsberg, and N. Petrelli. Initial Clinical (phase I) trial of TLCD-99 (doxorubicin encapsulated liposomes). Cancer Res. 53: 2796–2802 (1993).
A. J. Baillie, A. T. Florence, L. R. Hume, G. T. Muirhead, and A. Rogerson. The preparation and properties of niosomes—non-ionic surfactant vesicles. J. Pharm. Pharmacol. 37: 863–868 (1985).
A. T. Florence, C. Cable, C. Cassidy, and S. B. Kaye. Nonionic surfactant vesicles as carriers of doxorubicin. In G. Gregoriadis, A. C. Allison, G. Poste, (eds.), Targeting of Drugs, Plenum Press, New York, 1990, pp 117–126.
A. Rogerson, J. Cummings, N. Willmott, and A. T. Florence. The distribution of doxorubicin in mice following administration in niosomes. J. Pharm. Pharmacol. 40: 337–342 (1988).
D. J. Kerr, A. Rogerson, G. J. Morrison, A. T. Florence, and S. B. Kaye. Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer, spheroid and xenograft. Br. J. Cancer 58: 432–436 (1988).
I. F. Uchegbu, J. A. Double, J. A. Turton, and A. T. Florence. The activity of doxorubicin niosomes against a resistant human ovarian cancer cell line. J. Pharm. Pharmacol. 45(S2): 1112 (1993).
J. A. Double and L. C. de Castro. Chemotherapy of transplantable adenocarcinomas of the colon in mice. II. Development and characterization of an ascitic line. Cancer Treat. Rep. 62: 85–90 (1978).
G. Powis. Metabolism and reactions of quinoid anticancer agents. Pharmacol. Therap. 35: 57–162 (1987).
I. F. Uchegbu, J. A. Turton, J. A. Double, and A. T. Florence. The biodistribution and pulmonary adverse effect of intraperitoneally administered doxorubicin niosomes. Biopharm. Drug Dispos. 15: 691–707.
J. Cummings, J. F. B. Stuart, and K. C. Calman. Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography. J. Chromatogr. 311: 125–133 (1984).
J. Cummings and C. S. McArdle. Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug. Br. J. Cancer 53: 835–838 (1986).
M. Gilbaldi. Biopharmaceutics and clinical pharmacokinetics (4th edition). Lea and Febiger, Philadelphia, 1991.
P. A. J. Speth, Q. G. C. M. van Hoesel, and C. Haanen. Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokin. 15: 15–31 (1988).
A. Gabizon, R. Shiota, and D. Papahadjopoulos. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Nat. Cancer Inst. 81: 1484–1488 (1989).
S. Druckmann, A. Gabizon, and Y. Barenholz. Separation of liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies. Biochim. Biophys. Acta. 980: 381–384 (1989).
R. L. Thies, D. W. Cowens, P. R. Cullis, M. B. Bally, and L. D. Mayer. Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal. Biochem. 188: 65–71 (1990).
J. Cummings, L. Anderson, N. Willmott, and J. F. Smyth. The molecular pharmacology of doxorubicin in vivo. Eur. J. Cancer 27: 532–535 (1991).
R. Preiss, R. Sohr, B. Kittelmann, E. Müller, and D. Haase. Investigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites. Int. J. Clin. Pharmacol. Therapy Toxicol. 27: 156–164 (1989).
M. N. Azmin, A. T. Florence, R. M. Handjani-Vila, J. F. B. Stuart, G. Vanlerberghe, and J. S. Whittaker. The effect of niosomes and polysorbate 80 on the metabolism and excretion of methotrexate in the mouse. J. Pharm. Pharmacol. 37: 237–242 (1985).
G. Partharasi, N. Udupa, P. Umadevi, and S. K. Pillai. Niosome encapsulation of vincristine sulphate: improved anticancer activity with reduced toxicity in mice. J. Drug Targ. 2: 173–182 (1994).
J. A. E. Balazsovits, L. D. Mayer, M. B. Bally, P. R. Cullis, M. McDonnell, R. S. Ginsberg, and R. E. Falk. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother. Pharmacol. 23: 81–86 (1989).
J. Vaage, E. Mayhew, D. Lasic, and F. Martin. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int. J. Cancer 51: 942–948 (1992).
S. K. Huang, K.-D. Lee, K. Hong, D. S. Friend, and D. Papahadjopoulos. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52: 5135–5143 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Uchegbu, I.F., Double, J.A., Turton, J.A. et al. Distribution, Metabolism and Tumoricidal Activity of Doxorubicin Administered in Sorbitan Monostearate (Span 60) Niosomes in the Mouse. Pharm Res 12, 1019–1024 (1995). https://doi.org/10.1023/A:1016210515134
Issue Date:
DOI: https://doi.org/10.1023/A:1016210515134